Patient-reported outcomes related to migraine burden among patients treated with standard-of-care preventive medications or calcitonin gene-related monoclonal antibodies: a United States and Europe cross-sectional survey
Patients with migraine in the overall population and Europe who received 3+ lines of preventive migraine therapy and were receiving CGRP mAbs/galcanezumab demonstrated enhanced HRQoL compared to those who received standard of care.
Authors
- Lucas Scharf
- Gilwan Kim (ORCID: https://orcid.org/0000-0003-1991-6644)
- Sarah Cotton (ORCID: https://orcid.org/0000-0003-1158-6345)
- Oralee J. Varnado (ORCID: https://orcid.org/0000-0001-8054-2544)
- James Jackson (ORCID: https://orcid.org/0000-0002-4171-5390)
Institutions
- Eli Lilly (United States) (US)
- Adelphi Group (United Kingdom) (GB)
Publication Details
- Journal
- Current Medical Research and Opinion
- Published
- 2024-11-11
- DOI
- https://doi.org/10.1080/03007995.2024.2427884
- Citations
- 3
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.16
Funders
- Eli Lilly and Company